M E Hegi

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi p53 transdominance but no gain of function in mouse brain tumor model
    M E Hegi
    Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Res 60:3019-24. 2000
  2. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
  3. ncbi Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    J Clin Oncol 28:2712-8. 2010
  4. ncbi Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:459-66. 2009
  5. ncbi New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy
    Amir R Dehdashti
    Department of Neurosurgery, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Neurosurg Focus 20:E6. 2006
  6. ncbi Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery BH 19 110, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland
    J Clin Oncol 26:4189-99. 2008
  7. ncbi Optimal role of temozolomide in the treatment of malignant gliomas
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Curr Neurol Neurosci Rep 5:198-206. 2005
  8. ncbi Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics of the Neurosurgery Departments of the University Hospitals, Lausanne, Switzerland
    Clin Cancer Res 10:1871-4. 2004
  9. ncbi Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    Anastasia Murat
    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Oncol 26:3015-24. 2008
  10. ncbi Chemoradiotherapy in malignant glioma: standard of care and future directions
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Clin Oncol 25:4127-36. 2007

Collaborators

Detail Information

Publications33

  1. ncbi p53 transdominance but no gain of function in mouse brain tumor model
    M E Hegi
    Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Res 60:3019-24. 2000
    ..In conclusion, Y236delta is transdominant but exerts no gain-of-function activity mediating a more penetrant tumor phenotype...
  2. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
    ....
  3. ncbi Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    J Clin Oncol 28:2712-8. 2010
    ..This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma...
  4. ncbi Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:459-66. 2009
    ..We report the final results with a median follow-up of more than 5 years...
  5. ncbi New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy
    Amir R Dehdashti
    Department of Neurosurgery, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Neurosurg Focus 20:E6. 2006
    ..In this short review the authors summarize the current role of TMZ chemotherapy in the management of GBM, with an emphasis on approved indications and practical aspects...
  6. ncbi Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery BH 19 110, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland
    J Clin Oncol 26:4189-99. 2008
    ..Herein we review the data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are testing resistance-modulating strategies...
  7. ncbi Optimal role of temozolomide in the treatment of malignant gliomas
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Curr Neurol Neurosci Rep 5:198-206. 2005
    ..This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment...
  8. ncbi Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics of the Neurosurgery Departments of the University Hospitals, Lausanne, Switzerland
    Clin Cancer Res 10:1871-4. 2004
    ..Expression of this excision repair enzyme has been associated with resistance to alkylating chemotherapy...
  9. ncbi Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    Anastasia Murat
    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Oncol 26:3015-24. 2008
    ..Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide...
  10. ncbi Chemoradiotherapy in malignant glioma: standard of care and future directions
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Clin Oncol 25:4127-36. 2007
    ....
  11. ncbi Correlative studies in neuro-oncology trials: should they influence treatment?
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne Chuv, 1011 Lausanne, Switzerland
    Curr Oncol Rep 8:54-7. 2006
    ..or move on, incorporate the markers for patient selection or stratification, aim at improving the modestly effective treatments by adding new drugs, and develop alternative therapy strategies for patients selected for their bad predictor?..
  12. ncbi Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma
    Verena Voelter
    Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Int J Cancer 123:1215-8. 2008
    ..However, these results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to iah chemotherapy with alkylating agents...
  13. ncbi p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade
    M Nozaki
    Department of Neurosurgery, University Hospital, Lausanne, Switzerland
    Brain Pathol 11:296-305. 2001
    ..Like p53, p73 is exceptionally easy to inactivate as a transcription factor by point mutation. Taken together, these results indicate that p53 and p73 serve very different functions in tumors...
  14. ncbi Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome
    Sophie Shnaper
    Department of Neurosurgery, Laboratory of Brain Tumor Biology and Genetics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Int J Cancer 125:2624-30. 2009
    ..007, log-rank test). In conclusion, MIC-1/GDF15 protein measured in the CSF may have diagnostic and prognostic value in patients with intracranial tumors...
  15. ncbi Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia
    Anastasia Murat
    Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne CHUV and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 4:e5947. 2009
    ..Our results associate hypoxia-driven tumor response with inflammation in glioblastoma, hence underlining the importance of tumor-host interaction involving the inflammatory compartment...
  16. ncbi Neuro-oncology: oligodendroglioma and molecular markers
    Roger Stupp
    Multidisciplinary Oncology Centre and Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University of Lausanne Hospitals, 1011 Lausanne, Switzerland
    Lancet Neurol 6:10-2. 2007
  17. ncbi Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes
    Sophie Godard
    Laboratory of Tumor Biology and Genetics, University Hospital (CHUV, 1011 Lausanne, Switzerland
    Cancer Res 63:6613-25. 2003
    ..The separating groups of genes were found by the unsupervised coupled two-way clustering method, and their classification power was validated by a supervised construction of a nearly perfect glioma classifier...
  18. ncbi Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1
    Michele Albertoni
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hosptial Lausanne, 1011 Lausanne, Switzerland
    Oncogene 21:4212-9. 2002
    ..Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities...
  19. ncbi Brain tumors: molecular biology and targeted therapies
    M E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne (CHUV, Lausanne
    Ann Oncol 17:x191-7. 2006
  20. ncbi INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma
    Yan Lachat
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital CHUV, BH19 110, Lausanne 1011, Switzerland
    Oncogene 23:6854-63. 2004
    ..This resistance may contribute to the cooperative tumorigenic effect selected for in human glioblastoma that may be of crucial clinical relevance for treatments specifically targeting EGFR/DeltaEGFR(2-7) in glioblastoma patients...
  21. ncbi Targeting brain-tumor stem cells
    Roger Stupp
    Nat Biotechnol 25:193-4. 2007
  22. ncbi Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice
    Yongbaek Kim
    Laboratory of Experimental Pathology National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA
    Toxicol Pathol 33:307-12. 2005
    ..The observed findings are similar in part to the genetic alterations reported in human brain tumors...
  23. ncbi Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma
    Ilse Vlassenbroeck
    OncoMethylome Sciences SA, Tour 5 GIGA B34, 3, Avenue de l Hôpital 11, 4000 Liege, Belgium
    J Mol Diagn 10:332-7. 2008
    ..This high-throughput test provides an important pharmacogenomic tool for individualized management of alkylating agent chemotherapy...
  24. ncbi Recent developments in the use of chemotherapy in brain tumours
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Hospital Rotterdam, P O Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 42:582-8. 2006
    ..Trials exploring the role of chemotherapy in low-grade glioma are ongoing. No standard chemotherapy is currently available for highly anaplastic glioma failing first-line temozolomide-based therapy...
  25. ncbi Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    Thierry Gorlia
    EORTC Data Centre, Brussels, Belgium
    Lancet Oncol 9:29-38. 2008
    ....
  26. ncbi Changing paradigms--an update on the multidisciplinary management of malignant glioma
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Oncologist 11:165-80. 2006
    ..This review summarizes recent developments, focusing on the clinical management of patients in daily neuro-oncology practice...
  27. ncbi Methylguanine methyltransferase testing in glioblastoma: when and how?
    Roger Stupp
    J Clin Oncol 25:1459-60. 2007
  28. ncbi Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale Bellaria Maggiore Hospital, Bologna, Italy
    Clin Cancer Res 14:957-60. 2008
    ..As with other targeted agents, prospective trials using specific criteria and standardized methods to evaluate tissue biomarkers are required to find predictors of EGFR inhibitors activity in high-grade glioma patients...
  29. ncbi Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization
    Katrin Lange
    Center for Biomedicine, Department of Clinical and Biological Sciences, University of Basel, Basel, Switzerland
    Cancer Res 67:6163-73. 2007
    ..Inhibition of tenascin-C in combination with blocking both endothelin receptors could present a strategy for sensitization of cancer and endothelial cells toward anoikis...
  30. ncbi Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment
    Katrin Lange
    Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland
    Cancer Res 68:6942-52. 2008
    ..These findings may in turn be relevant for diagnostic or therapeutic applications targeting cancer...
  31. ncbi Growth promoting signaling by tenascin-C [corrected]
    Christian Ruiz
    Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung, Basel, Switzerland
    Cancer Res 64:7377-85. 2004
    ....
  32. ncbi Prognostic factors for low-grade gliomas
    Roger Stupp
    Multidisciplinary Oncology Center, University Hospital (CHUV, 46, Rue du Bugnon, CH-1011 Lausanne, Switzerland
    Semin Oncol 30:23-8. 2003
    ..However, other than surgery, the optimal types and sequence of therapies are not yet established. Improvements in defining prognostic factors will assist in low-grade glioma management...
  33. ncbi MGMT methylation status: the advent of stratified therapy in glioblastoma?
    Peter Hau
    Klinikum der Universitat Regensburg, Klinik und Poliklinik für Neurologie am Bezirksklinikum, 93053 Regensburg, Germany
    Dis Markers 23:97-104. 2007
    ....